Samsara BioCapital’s Janux Therapeutics JANX Stock Holding History

Samsara BioCapital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,263	Closed	-$603K	–	41
2024 Q4	$603K	Sell	11,263 -11,263	-50%	-$596K	0.08%	36
2024 Q3	$1.02M	Sell	22,526 -22,526	-50%	-$980K	0.2%	32
2024 Q2	$1.89M	Sell	45,052 -135,155	-75%	-$6.35M	0.4%	29
2024 Q1	$6.78M	Sell	180,207 -180,207	-50%	-$3.92M	1.05%	20
2023 Q4	$3.87M	Hold	360,414	–	–	0.6%	25
2023 Q3	$3.63M	Hold	360,414	–	–	1.11%	24
2023 Q2	$4.28M	Hold	360,414	–	–	0.75%	23
2023 Q1	$4.36M	Hold	360,414	–	–	0.9%	22
2022 Q4	$4.75M	Hold	360,414	–	–	1.02%	20
2022 Q3	$4.88M	Hold	360,414	–	–	1.14%	23
2022 Q2	$4.4M	Sell	360,414 -51,457	-12%	-$609K	1.17%	22
2022 Q1	$5.91M	Hold	411,871	–	–	1.49%	15
2021 Q4	$8.13M	Hold	411,871	–	–	1.58%	16
2021 Q3	$8.91M	Sell	411,871 -196,078	-32%	-$5.64M	1.4%	19
2021 Q2	$15.2M	Buy	+607,949	New	+$13.5M	1.87%	11

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Samsara BioCapital's JANX Position: Q1 2025 in Review

Samsara BioCapital sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 11,263 shares — an estimated $603K sold.

Samsara BioCapital first reported a position in JANX in Q2 2021 and held it in 15 quarters. The position peaked at $15.2M in Q2 2021. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

Samsara BioCapital reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
Samsara BioCapital sold 11,263 Janux Therapeutics shares in Q1 2025, an estimated $603K.
Samsara BioCapital first reported a position in Janux Therapeutics in Q2 2021 and held it in 15 quarters.
Samsara BioCapital's Janux Therapeutics position peaked at $15.2M in Q2 2021.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.